Qingqing Yi
Known title: DirectorCIK: 0001662556
Associated companies
Transaction History
| ONC | ▼ Sell | Open Market | 235 | $66K | 6/1/2026 | View on chart |
| ONC | ▼ Sell | Other | 29,614 | $0 | 6/10/2025 | View on chart |
| ONC | ▲ Buy | Grant | 10,985 | $0 | 5/21/2025 | View on chart |
| ONC | ▲ Buy | Grant | 16,341 | $0 | 6/5/2024 | View on chart |
| ONC | ▲ Buy | Grant | 12,922 | $0 | 6/15/2023 | View on chart |
| ONC | ▼ Sell | Other | 7,800 | $0 | 8/22/2022 | View on chart |
| ONC | ▲ Buy | Grant | 16,692 | $0 | 6/22/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
BeOne Medicines Receives Rating Upgrade and Added to Top-Rated List
BeOne Medicines Ltd. has been upgraded to a top rating by analysts. It was also added to a list of top-rated stocks for the week. The upgrade follows recent earnings and infrastructure updates discussed in a broader market analysis. The move may influence investor perception of the company.
BeOne Medicines Receives Rating Upgrade and Added to Top-Rated List. BeOne Medicines Ltd. has been upgraded to a top rating by analysts. It was also added to a list of top-rated stocks for the week. The upgrade follows recent earnings and infrastructure updates discussed in a broader market analysis. The move may influence investor perception of the company.